Back to Results
First PageMeta Content
Organic chemistry / Piperazines / Health / Orphan drugs / Organofluorides / Chronic myelogenous leukemia / Imatinib / Nilotinib / Philadelphia chromosome / Pyrimidines / Medicine / Pyridines


Decision modelling using time on treatment data: evaluating the survival benefit of nilotinib versus imatinib in patients with chronic phase Ph+ CML
Add to Reading List

Document Date: 2014-06-04 14:54:10

Open Document

File Size: 152,82 KB

Share Result on Facebook

City

Philadelphia / ENESTnd Great / Bilbao / London / Bicester / Surrey / /

Company

Novartis Pharmaceuticals UK Ltd. / 3Novartis Pharmaceuticals UK Ltd / /

Country

United Kingdom / Spain / /

Currency

GBP / /

Facility

University of Sheffield / /

Holiday

Assumption / /

Organization

University of Sheffield / Sheffield / UK National Health Service / British Medical Association / Pharmaceutical Society / /

/

Product

cytarabine / /

ProvinceOrState

South Dakota / /

Technology

transplantation / /

URL

http /

SocialTag